Compounds Lymphosarcoma PC-3 Prostate Cancer Cells Myeloid Leukemia Cancer Cells Mesangial Cells PC1 3±2.5 4±3.5 4±2.9 15±2.8 PC2 2±2.6 2±2.7 3±2.5 13±.5 PC3 2±2.7 4±2.5 3±4.6 12±2.5 PC4 3±3.6 2±2.8 2±2.5 14±3.5 PC5 2±2.8 3±2.7 4±1.7 11±2.6 PC6 2±1.5 2±2.6 2±2.5 13±2.8 Cisplatin 6±4.5 8±2.5 10±3.7 4±2.4 DMSO NA NA NA NA GI50 (mean ± S.D.) refers to the concentration required to have 50% cell-growth inhibition; (-) indicates that the isolated is inactive (negative at 100 or GI50>100 μM); N/A: no data available

Table 2: The effects of the PC-series of compounds (PC1-PC6) on lyphosarcoma, PC-3 prostate, and myeloid leukemia cancer cells and mesangial cells.